article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

470% price increases

World of DTC Marketing

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 57
article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

” Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS average at around 7%, before skyrocketing to 19% in 2022 ahead of a government agreed cap at 15%. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.”

Pharma 70
article thumbnail

How Value Based Health Care Will Impact Medical Sales

Spotio

The goals are to increase quality, decrease costs and turn health care into a competitive marketplace. They cite a 24% increase in drug costs per hospital admission in 2014 and a 12% increase in 2015. Healthcare as a competitive market is a new idea. Expect short term upheaval and long term economic impacts.

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). More recently, Biogen has been facing competition from dimethyl fumarate generics.

article thumbnail

AbbVie, Lilly pull out of UK voluntary drug pricing agreement

pharmaphorum

Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS averaged at around 7%, but skyrocketed to 19% in 2022 ahead of a government-agreed cap at 15%, and rose again to 26.5% in 2022. . ” The post AbbVie, Lilly pull out of UK voluntary drug pricing agreement appeared first on.